Branded generics vs. commodity generics isnt a pricing debateits a trust debate.
In the generic drug market, the conventional wisdom says the lowest price wins. But the reality is more nuanced: when patients, prescribers, and payers choose between esse…

Pharma has a timing problemand its getting more expensive.
In a world where launch windows are measured in weeks (and sometimes days), filing later isnt just a legal misstep. Its a commercial disadvantage. The companies winning market share arent simpl…

Dont Get Blindsided: The Critical Drug Patent Mistakes to Avoid in MA Due Diligence
In mergers and acquisitions, the biggest surprises rarely come from the obvious places. They come from the fine printespecially in life sciences, where a single patent …

Post-Approval Patents: The Hidden LEOE Risk Map Pharma Cant Afford to Ignore
In the rush to launch, many teams treat post-approval patents like background noisefiled, tracked, and occasionally litigated. But the real risk isnt just whether a patent exi…

Post-Approval Patents: The Hidden Loe Risk Map Pharma Cant Afford to Ignore
Most teams think the patent story ends at approval.
They shouldnt.
In the post-approval world, the real risk often hides in plain sight: patents that are filed, asserted, or st…

Beyond 20 Years: What Actually Determines a Drugs Market Exclusivity
The 20-year patent story is comfortingsimple, linear, and easy to model. But if you work in pharma, you know the truth is messier: a drugs market exclusivity is rarely decided by a si…

Pharma mega-deals dont happen because of synergy slides. They happen because of exclusivity.
Behind every headline acquisitionevery blockbuster asset changing hands for billionstheres a quiet, technical question that determines whether a buyer is buyin…

Patent cliffs arent just a legal eventtheyre a pricing event. And if youre still treating them like a quarterly surprise, youre already late.
In pharma, the patent cliff is often framed as a calendar problem: a date approaches, exclusivity ends, generi…

Post-Approval Isnt AfterIts the Next Battle. Heres the Patent Strategy Most Teams Underestimate.
In pharma, the hardest part is often framed as the pre-approval sprint: clinical data, regulatory filings, and the race to market. But the real risk doesnt…

Post-approval is where the real IP game starts.
Most teams obsess over getting to approval—then quietly assume the hard part is over. It isn’t. In the months and years after launch, your product becomes a target: for generic challengers, for “evergre…